Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitravatinib (Primary) ; Tislelizumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors BeiGene

    • Most Recent Events

    • 10 Jan 2023 Status changed from active, no longer recruiting to completed.
    • 09 Aug 2022 Results (n=24; Between May 12, 2020 and February 10, 2021; data cut-off November 8, 2021) assessing safety, tolerability, and antitumor activity of sitravatinib and tislelizumab in patients with programmed death-ligand 1 positive, squamous non-small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
    • 09 Aug 2022 Results (n=22) assessing results from patients with programmed death-ligand 1 positive, non-squamous non-small cell lung cancer , presented at the 2022 World Conference on Lung Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top